Many former FDA officials, both politically-appointed leaders and those from the career ranks, as well as numerous FDA scholars have advocated for increased FDA independence in varied forms, and for g...

The rushed launch of a Medicare pilot to use AI for prior authorization led to delayed care in some instances, new documents reveal.

Congress required CMS to offer a fallback prescription drug plan when no private PDP was available. Rather than waiting until total market failure, the agency should explore creating a federally facil...

This Viewpoint describes potential concerns and opportunities with a single-trial default for US Food and Drug Administration (FDA) drug approval.

Despite the FTC’s promises, its settlements with PBMs will not be fully effective at accomplishing their stated goals. One concern of note: The settlements neglect the recent development of PBMs marke...

The Bridge program, which began July 1, makes some Medicare beneficiaries eligible for obesity drugs for $50 a month. CVS and Walgreens say they've each already filled 100,000 such prescriptions.

Several conservative states will require proof from people who say they're too sick to work.

More people who lost coverage after congressional Republicans ended enhanced federal subsidies are now seeking care in emergency rooms and unable to pay bills.

Agency scientists are advising against allowing widespread use of several peptide injections. Robert F. Kennedy Jr., the health secretary, has said people should be free to experiment.

Medicare Drug Price Negotiation Program: Draft Guidance for Manufacturer Effectuation of the Maximum Fair Price in 2028

Democracy Forward keeps filing lawsuits seeking subsidies the law doesn’t allow.

Reducing Medicare payments for 340B drugs is the latest proposal focused on the hotly debated drug discount program.

This Viewpoint discusses the US Centers for Medicare & Medicaid Services’ (CMS) extension of the Medicare Glucagon-Like Peptide-1 (GLP-1) Bridge and outlines unanswered questions related to how th...

The proposed changes are relatively modest, yet they represent an important procedural step forward in the implementation of the Medicare Drug Price Negotiation Program.

Peer review now optional, political staff would screen grants for forbidden topics.

States dealing with budget shortfalls are facing tens of millions of dollars in new costs ahead of the federal Jan. 1 deadline.

The proposed rule aims to improve prior authorization for prescription drugs by establishing and requiring electronic prior authorization, setting coverage decision deadlines, and promoting transparen...

A new pilot Medicaid program — GENEROUS — combines centralized pharmaceutical-coverage negotiations with most-favored-nation pricing in an effort to lower drug costs, but it has some limitations.

CMS’s efforts to expand Medicare coverage of GLP-1s for obesity could provide substantial benefits to millions of Medicare beneficiaries, given the potential demand for these highly effective medicati...

This brief describes current coverage of GLP-1s in Medicare and Medicaid, the Centers for Medicare & Medicaid Services’ (CMS) efforts to expand access and lower costs for GLP-1s through temporary demo...

By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered: Section 1.  Purpose and